Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus CARMOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus CARMOL HC.
ACLOVATE vs CARMOL HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid